Learn from Mark VanNess and 840+ other industry-leading experts. Browse Plans
Mark VanNess
PhD
J. Mark VanNess, PhD, is a cardiovascular biologist and Distinguished Professor in the department of Health and Exercise Science at the University of the Pacific. He studied biology, chemistry, and exercise science as an undergraduate student and exercise physiology for his master's degree. He received his doctoral degree from the program in Neuroscience at Florida State University. He has postdoctoral training from the University of Texas Health Science Center in San Antonio in Pharmacology and Physiology, and presently teaches at the University of the Pacific. His primary research interest focuses on ME/CFS and the cardiovascular and metabolic abnormalities that are unmasked by exercise testing in the illness. His collaboration with the Workwell Foundation has helped in the identification and description of post-exertional malaise in ME/CFS. Objective evidence documenting illness severity helps with treatment and efficacy for interventions.
Courses with Mark VanNess
Browse Course CatalogME/CFS Part 1: Introduction and Identification
Presented by Todd E. Davenport, PT, DPT, MPH, OCS, Staci Stevens, MA, and Mark VanNess, PhD
ME/CFS Part 1: Introduction and Identification
This lesson is part one of a two-course series. Proceed to Part Two after completing this course.
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) causes severely disabling fatigue within the context of a constellation of unusual signs and symptoms, which are associated with over-exertion. Because people with ME/CFS present with a whole host of clinical findings, there are multiple reasons for entry into medical and rehabilitation settings. The multifactorial clinical presentation of ME/CFS emphasizes the need for clinicians to recognize ME/CFS, in order to advocate for patients/clients with possible ME/CFS and to direct its appropriate management. The pathoetiology of ME/CFS is becoming better understood, and there is emerging evidence based on this pathoetiological evidence to support best practices in analeptic management strategies for people with ME/CFS.
This two-part course series provides the opportunity for attendees to receive the latest information in recognition, etiology, and analeptic management of patients with ME/CFS from a panel of established researchers and clinicians. In this session, the presenters will (i) summarize the clinical features ME/CFS with respect to optimal identification and differential diagnosis; (ii) describe the pathoetiology underlying the clinical features of ME/CFS; and (iii) provide an actionable framework for optimal analeptic management of individuals with ME/CFS that is based on current scientific evidence.
ME/CFS Part 2: Etiology and Analeptic Management
Presented by Todd E. Davenport, PT, DPT, MPH, OCS, Staci Stevens, MA, and Mark VanNess, PhD
ME/CFS Part 2: Etiology and Analeptic Management
This lesson is the second part of the two-course series. Complete Part One before beginning this course.
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) causes severely disabling fatigue within the context of a constellation of unusual signs and symptoms, which are associated with overexertion. Because people with ME/CFS present with a whole host of clinical findings, there are multiple reasons for entry into medical and rehabilitation settings. The multifactorial clinical presentation of ME/CFS emphasizes the need for clinicians to recognize ME/CFS, in order to advocate for patients/clients with possible ME/CFS and to direct its appropriate management. The pathoetiology of ME/CFS is becoming better understood, and there is emerging evidence based on this pathoetiological evidence to support best practices in analeptic management strategies for people with ME/CFS.
This two-part course series provides the opportunity for attendees to receive the latest information in recognition, etiology, and analeptic management of patients with ME/CFS from a panel of established researchers and clinicians. In this session, the presenters will (i) summarize the clinical features ME/CFS with respect to optimal identification and differential diagnosis; (ii) describe the pathoetiology underlying the clinical features of ME/CFS; and (iii) provide an actionable framework for optimal analeptic management of individuals with ME/CFS that is based on current scientific evidence.
Start any course for free!
Get access to the first chapter of all 2600+ courses when you create a free account.
Sign Up for Free